BLOOD COAGULATION FACTOR

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 第VIII因子(FVIII)是一种175 kDa的关键止血蛋白，对血液凝固是必不可少的。FVIII基因的自然突变导致轻微到严重的A型血友病，这是一种威胁生命的血液疾病，影响5000名男性人口中的一人(Wacey等人，1996年)。治疗这种疾病的唯一方法是静脉注射FVIII，Stoilova-McPhie使用电子显微镜研究了FVIII的膜结合结构(Parmenter和Stoilova-McPhie，2008；Stoilova-McPhie等人，2008)。 通过低温电子显微镜确定膜结合凝血因子Va和凝血因子VIIIa与脂质纳米管的结构是本项目的主要目标。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Factor VIII (FVIII) is a key haemostasis protein of 175 kDa, essential for blood clotting. Natural mutations in FVIII result in mild to severe Haemophilia type A, a life-threatening blood condition affecting one in 5000 of the male population (Wacey et al., 1996). The sole cure for this condition is intravenous administration of FVIII, whose membrane-bound structure has been studied by Stoilova-McPhie using electron microscopy (Parmenter and Stoilova-McPhie, 2008; Stoilova-McPhie et al., 2008). Defining the structure of membrane-bound blood coagulation Factor Va and Factor VIIIa attached to lipid nanotubes by Cryo-electron microscopy is the primary goal of this project.